<meta charset='utf-8'>
<base target='_blank'>

        <style>
            body{font-family:system-ui,sans-serif;max-width:50rem;margin:2rem auto;line-height:1.6;padding:1rem}
            img,iframe{max-width:100%}
            .post-content{background:#f9f9f9;padding:1rem;border-radius:5px;margin:1rem 0}
            .archive-header{background:#f0f8ff;border:1px solid #e0e0e0;border-radius:5px;padding:0.75rem;margin-bottom:1rem;font-size:0.9rem}
            .archive-info{margin-bottom:0.5rem;color:#666}
            .archive-source{color:#666}
            .archive-header a{color:#007acc;text-decoration:none}
            .archive-header a:hover{text-decoration:underline}
            @media (prefers-color-scheme: dark) {
                .archive-header{background:#1a1a2e;border-color:#333;color:#e0e0e0}
                .archive-info, .archive-source{color:#ccc}
                .archive-header a{color:#66b3ff}
            }
        </style>
        
<div class="archive-header">
        <div class="archive-info">
            <strong>ğŸ“„ Archived:</strong> 2025-08-31 12:24:29 UTC
        </div>
        <div class="archive-source">
            <strong>ğŸ”— Source:</strong> <a href="https://papers.lgbt/papers/prog">https://papers.lgbt/papers/prog</a>
        </div>
    </div>
    <script>
        // Archive metadata for cache management
        window.archiveData = {
            url: 'https://papers.lgbt/papers/prog',
            archivedAt: "2025-08-31T12:24:29.217941+00:00Z",
            timestamp: 1756643069217
        };
    </script>
    <hr>
<main class="paper-main flex-1 max-w-4xl mx-auto px-10 sm:px-12 md:px-16 lg:px-20 xl:px-28 2xl:px-36 py-8 lg:py-12" style="max-width: 76rem;"><div class="lg:hidden mb-8"><h3 class="text-xs font-medium uppercase tracking-wider text-muted-foreground mb-2">/prog</h3><h1 class="text-2xl font-medium text-foreground mb-2">progesterone in transsexual female hrt: a review of timing, biology, and what we (donâ€™t yet) know</h1><p class="text-sm text-muted-foreground">by emily/endocrinemoder/adenine</p></div><div class="bg-background p-6 mb-8 border"><h2 class="text-lg font-medium text-foreground mb-3">abstract</h2><p class="text-foreground leading-relaxed">this review tackles a hard question in transsexual female care: when to add progesterone. 

    mechanistically, mammary development runs in two phases. first, estradiol (with gh/igfâ€‘1) pushes ductal elongation and branching from terminal end buds; later, progesterone (with prolactin) leans the system toward lobuloâ€‘alveolar differentiation and secretory readiness. that division of labor matters for sequencing. adding progesterone too early, before estradiol has built a decent ductal scaffoldâ€”could, in theory, nudge tissue into differentiation at the expense of further branching, ultimately limiting ductal complexity and perhaps final breast size. animal models and cis puberty biology make that hypothesis biologically plausible; direct proof for or against in trans cohorts is not yet here. human data to date: (i) cis/animal literature strongly separates estrogenâ€‘led branching from progesteroneâ€‘led alveologenesis; (ii) transsexual female groups show early, frontâ€‘loaded growth under estradiol with modest absolute volumes after a year; (iii) a small, short prospective study of 100â€¯mg oral micronized progesterone (omp) showed no breast staging benefit at 3 months; (iv) patientâ€‘reported surveys suggest perceived benefits; and (v) a randomized trial testing estradiolâ€¯Â±â€¯omp with 3â€‘d volume endpoints is underway. pending stronger trials, a cautious, timeâ€‘sequenced approach, defer progesterone until ~6â€“12 months after starting estradiol, once tanner b2â€“b3 budding is evident, best harmonizes with puberty physiology while minimizing the chance of getting ahead of the biology. </p></div><div class="lg:hidden mb-8"><div class="flex flex-wrap gap-2"><span class="px-3 py-1 bg-secondary text-secondary-foreground text-sm">progesterone</span><span class="px-3 py-1 bg-secondary text-secondary-foreground text-sm">roadmap</span><span class="px-3 py-1 bg-secondary text-secondary-foreground text-sm">breast development</span><span class="px-3 py-1 bg-secondary text-secondary-foreground text-sm">estradiol</span><span class="px-3 py-1 bg-secondary text-secondary-foreground text-sm">CHT</span><span class="px-3 py-1 bg-secondary text-secondary-foreground text-sm">HRT</span></div></div><div class="paper-container bg-background border mx-auto max-w-5xl px-6 md:px-10 lg:px-14 py-10" style="max-width: 70rem;"><article class="prose prose-neutral prose-lg max-w-none [&amp;_*]:break-words [&amp;_table]:prose-table [&amp;_thead_th]:uppercase [&amp;_thead_th]:tracking-wide [&amp;_thead_th]:text-xs [&amp;_h1]:scroll-mt-24 [&amp;_h2]:scroll-mt-24 [&amp;_h3]:scroll-mt-24 [&amp;_h4]:scroll-mt-24 [&amp;_h5]:scroll-mt-24 [&amp;_h6]:scroll-mt-24 [&amp;_a]:text-blue-600 hover:[&amp;_a]:text-blue-700 dark:[&amp;_a]:text-blue-400 dark:hover:[&amp;_a]:text-blue-500 underline-offset-4" style="--para-space: 0.5em;"><p><strong>progesterone in transsexual female hrt: a review of timing, biology, and what we (donâ€™t yet) know</strong></p>
    <h2><strong>introduction</strong></h2>
    <p>crosssex hormone therapy (CHT) for transsexual female individuals aims to induce breast development, shift body composition, and align secondary sex characteristics with gender. with breasts, some individuals achieve satisfactory fullness with estradiol alone, but many plateau early with small absolute volumes despite appropriate estradiol exposure and testosterone suppression. observational program data and narrative reviews consistently note that <strong>most measurable growth happens early</strong>, and that even after years, many remain below an aâ€‘cup equivalent. fueling interest in adjuncts such as progesterone. the question is not â€œprogesterone: yes or no?â€ but <strong>â€œprogesterone: when?â€</strong>. (<a href="https://pubmed.ncbi.nlm.nih.gov/29165635/">PubMed</a>, <a href="https://onlinelibrary.wiley.com/doi/10.1111/joim.13441">Wiley Online Library</a>, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12012776/">PMC</a>)</p>
    <hr>
    <h2><strong>the twoâ€‘phase frame: ducts first, then lobuloâ€‘alveoli</strong></h2>
    <p><strong>phase 1 â€” branching morphogenesis.</strong> at puberty, estradiol acting within a gh/igfâ€‘1 milieu drives terminal end buds (tebs) to invade the fat pad, elongate, and bifurcate, laying the primary and secondary ductal tree. this is the <em>branching</em> state: high proliferation at tebs, lateral sprouting, and progressive filling of the fat pad. estradiolâ€™s priming also induces progesterone receptor and prolactin receptor expression in ductal epithelium, setting the stage for the next phase. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3404495/">PMC</a>, <a href="https://academic.oup.com/endo/article/141/8/2982/2988701">Oxford Academic</a>)</p>
    <p><strong>phase 2 â€” sideâ€‘branching and alveologenesis.</strong> once a ductal scaffold exists, progesterone signaling (largely via prâ€‘b) promotes tertiary sideâ€‘branching and, with prolactin, the <strong>lobuloâ€‘alveolar</strong> program that ultimately supports lactation. while full alveolar expansion is most dramatic in pregnancy, progesteroneâ€™s imprint on sideâ€‘branching and early alveolar buds is well described in nonpregnant models. mechanistically, progesterone acts through paracrine mediators (e.g., rankl, wnt programs) and mitogenic targets (e.g., cyclin d1). (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4596764/">PMC</a>, <a href="https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr1411">BioMed Central</a>, <a href="https://www.pnas.org/doi/10.1073/pnas.0915148107">PNAS</a>)</p>
    <p><strong>takeaway.</strong> the mammary gland toggles between a <strong>growâ€‘andâ€‘branch</strong> state (estradiolâ€‘dominant) and a <strong>differentiateâ€‘andâ€‘fill</strong> state (progesteroneâ€¯Â±â€¯prolactin). trying to run both programs at once is biologically awkward. singleâ€‘cell/spatial work in mice even maps a <strong>tradeoff</strong> between proliferative/branching programs and lineageâ€‘differentiation programs under endocrine cues. (<a href="https://www.sciencedirect.com/science/article/pii/S2211124723013050">ScienceDirect</a>)</p>
    <hr>
    <h2><strong>why timing matters: the â€œtooâ€‘early progesteroneâ€ hypothesis</strong></h2>
    <p><strong>the hypothesis.</strong> introduce progesterone before estradiol has meaningfully elongated and branched ducts (i.e., preâ€‘ or veryâ€‘early budding), and you risk shifting epithelial fate toward alveolar differentiation while curtailing further tebâ€‘driven branching, potentially locking in a simpler ductal tree and limiting later capacity for volume/shape change. this is a <strong>theoretical</strong> concern, not a proven harm, but it is biologically coherent given (i) estrogenâ€™s lead role in ductal outgrowth; (ii) progesteroneâ€™s drive toward sideâ€‘branching and alveologenesis; and (iii) evidence of a proliferationâ†”differentiation tradeoff. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3404495/">PMC</a>, <a href="https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr1411">BioMed Central</a>, <a href="https://www.sciencedirect.com/science/article/pii/S2211124723013050">ScienceDirect</a>)</p>
    <p><strong>what cis puberty teaches about sequencing.</strong> in cis girls, thelarche (breast budding) is typically the first clinical sign of puberty; <strong>consistent luteal progesterone exposure</strong> only becomes regular after ovulatory cycles settle, often years later. in other words, nature tends to <strong>build ducts first</strong> under estradiol and only <strong>layers regular progesterone later</strong>. mirroring that tempo in transsexual female CS is a reasonable default. (<a href="https://www.ncbi.nlm.nih.gov/books/NBK534827/">NCBI</a>, <a href="https://pm.amegroups.org/article/view/4978/html">pm.amegroups.org</a>, <a href="https://renaissance.stonybrookmedicine.edu/system/files/Early%20Puberty.pdf">Renaissance School of Medicine</a>)</p>
    <hr>
    <h2><strong>evidence base (and its gaps)</strong></h2>
    <h3><strong>1) cis biology &amp; animal models (strong on mechanism, not final outcomes)</strong></h3>
    <ul>
    <li>estrogenâ€¯+â€¯gh/igfâ€‘1 is sufficient to trigger pubertal ductal outgrowth with classic teb dynamics; progesterone is <em>dispensable</em> for initial elongation in several models but <em>required/sufficient</em> for sideâ€‘branching and alveolar budding/differentiation once ducts exist. multiple groups demonstrate progesteroneâ€‘induced tertiary branching and alveolar formation. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3404495/">PMC</a>, <a href="https://academic.oup.com/endo/article/146/3/1170/2500345">Oxford Academic</a>)  </li>
    <li>progesteroneâ€™s paracrine network (rankl, wnt4, cyclin d1) and estradiolâ€™s priming of pr/prlr support a staged handoff, estrogen sets competence; progesterone executes differentiation. (<a href="https://academic.oup.com/endo/article/141/8/2982/2988701">Oxford Academic</a>, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8052380/">PMC</a>)  </li>
    <li>singleâ€‘cell/spatial atlases highlight endocrineâ€‘linked <strong>state switching</strong> between proliferative branching and lineage commitment, reinforcing the intuitive â€œdonâ€™t ask the gland to do both at onceâ€ message. (<a href="https://www.sciencedirect.com/science/article/pii/S2211124723013050">ScienceDirect</a>)</li>
    </ul>
    <p><strong>mechanistic bottom line:</strong> the <strong>orderâ€‘ofâ€‘operations</strong> model (grow ducts under estradiol; differentiate under progesterone) is robust across mammals. that doesnâ€™t prove timing harms/benefits in trans adults, but it makes the timing question worth caring about. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3404495/">PMC</a>)</p>
    <h3><strong>2) transsexual female groups (what actually happens with estradiol alone, and what people report with progesterone)</strong></h3>
    <ul>
    <li><strong>estradiol alone</strong>: prospective data show breast development is <strong>modest and frontâ€‘loaded</strong>, with the <strong>majority of measurable change in the first 6 months</strong> after starting CHT; many remain below an aâ€‘cup after a year, and augmentation rates are high. (<a href="https://pubmed.ncbi.nlm.nih.gov/29165635/">PubMed</a>, <a href="https://onlinelibrary.wiley.com/doi/10.1111/joim.13441">Wiley Online Library</a>, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12012776/">PMC</a>)  </li>
    <li><strong>patientâ€‘reported experience</strong>: a 2025 crossâ€‘sectional survey of transsexual individuals using progestogens found that <strong>most users perceived improved breast development</strong>; such surveys are valuable for hypothesisâ€‘generation but are susceptible to selection and expectation biases. (<a href="https://www.sciencedirect.com/science/article/pii/S1530891X25009437">ScienceDirect</a>)</li>
    </ul>
    <h3><strong>3) randomized trials (the missing piece)</strong></h3>
    <ul>
    <li>a multicenter <strong>randomized</strong> study is underway testing <strong>estradiolâ€¯Â±â€¯oral micronized progesterone</strong> with <strong>3â€‘d breast volume</strong> as the primary endpoint; the published protocol frames safety and dosing (e.g., 200â€“400â€¯mg) and sets up the first highâ€‘quality efficacy readout. as of today, <strong>results are pending</strong>. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10734173/">PMC</a>, <a href="https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-023-00724-4">BioMed Central</a>)</li>
    </ul>
    <p><strong>evidence summary:</strong> the mechanistic case for <strong>timing</strong> is coherent; realâ€‘world outcomes in trans populations remain <strong>uncertain</strong>. there is no definitive proof that progesterone increases volume, or that starting it early harms it. nonetheless, sequencing it <strong>after estradiolâ€‘initiated budding</strong> is a lowâ€‘regret choice aligned with puberty biology and current observational signals. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3404495/">PMC</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/29165635/">PubMed</a>)</p>
    <hr>
    <h2><strong>practical timing: why â€œafter 6â€“12 monthsâ€ is a reasonable default</strong></h2>
    <ul>
    <li>by ~6â€“12 months on estradiol, most patients are at <strong>tanner b2â€“b3</strong> (budding to early mound), and the early estradiolâ€‘led <strong>branching burst</strong> is underway; adding progesterone <strong>after</strong> this point emulates cis puberty sequencing and is <em>less likely</em> to push the gland out of branching mode prematurely. (<a href="https://www.ncbi.nlm.nih.gov/books/NBK534827/">NCBI</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/29165635/">PubMed</a>)  </li>
    <li>the <strong>frontâ€‘loaded</strong> time course of estradiolâ€‘only growth (largest gains in months 0â€“6) further supports waiting until the initial branching wave has crested before deliberately inviting alveolar programming. (<a href="https://pubmed.ncbi.nlm.nih.gov/29165635/">PubMed</a>)</li>
    </ul>
    <p><strong>translation:</strong> if your goal is to maximize the ductal scaffold before layering alveolar fullness, <strong>wait for budding</strong>, then consider progesterone, understanding that its volumetric benefit is unproven and may be subtle or personâ€‘specific. (<a href="https://pubmed.ncbi.nlm.nih.gov/29165635/">PubMed</a>)</p>
    <hr>
    <h2><strong>frequently asked timing scenarios (biologically informed takes)</strong></h2>
    <ol>
    <li><strong>starting progesterone at month 0 with estradiol.</strong> <strong>not preferred</strong> on biological grounds: risks nudging toward alveolar programs before ducts expand, with no evidence of net volumetric gain. if done, counsel that effects (positive or negative) are unproven. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3404495/">PMC</a>, <a href="https://www.sciencedirect.com/science/article/pii/S2211124723013050">ScienceDirect</a>)  </li>
    <li><strong>adding progesterone at 6â€“12 months, once budding is clear.</strong> <strong>reasonable default</strong> to mirror cis puberty sequencing; aligns with estradiolâ€‘frontâ€‘loaded growth and likely minimizes any theoretical â€œearly differentiationâ€ penalty. (<a href="https://pubmed.ncbi.nlm.nih.gov/29165635/">PubMed</a>, <a href="https://pm.amegroups.org/article/view/4978/html">pm.amegroups.org</a>)  </li>
    <li><strong>adding progesterone after 12â€“24 months because growth plateaued.</strong> also reasonable, with the caveat that plateau is common and absolute volumes may stay modest; consider documenting changes with standardized photography or 3â€‘d tools when possible. (<a href="https://journals.lww.com/prsgo/_layouts/15/oaks.journals/downloadpdf.aspx?an=01720096-202409000-00009&amp;utm_source=chatgpt.com">Lippincott Journals</a>, <a href="https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0305059&amp;utm_source=chatgpt.com">PLOS</a>)</li>
    </ol>
    <hr>
    <h2><strong>conclusions</strong></h2>
    <ul>
    <li>mammary biology really does split: <strong>estradiol builds the ducts; progesterone matures the alveoli</strong>. starting progesterone <strong>too early</strong> is a <em>plausible</em> way to push tissue into the wrong program at the wrong time. this is <strong>theoretical</strong>, not proven harm. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3404495/">PMC</a>, <a href="https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr1411">BioMed Central</a>)  </li>
    <li>adding progesterone <strong>after 6â€“12 months of estradiol</strong>, once budding is evident, <strong>tracks natural puberty</strong> and is <strong>less likely</strong> to hinder ductal expansion. it may or may not add meaningful volume; (<a href="https://pm.amegroups.org/article/view/4978/html">pm.amegroups.org</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/29165635/">PubMed</a>, <a href="https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-023-00724-4">BioMed Central</a>)  </li>
    <li>until we have definitive data, <strong>transparent counseling + careful sequencing + measurement</strong> beats allâ€‘orâ€‘nothing takes. (<a href="https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0305059&amp;utm_source=chatgpt.com">PLOS</a>)</li>
    </ul>
    <hr>
    <h3><strong>selected references (linked inline above)</strong></h3>
    <ul>
    <li>macias &amp; hinck. <em>mammary gland development.</em> 2012 (review). estradiol â†’ ductal growth; progesterone â†’ alveolar programs. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3404495/">PMC</a>)  </li>
    <li>arendt etâ€¯al. <em>form and function: how estrogen and progesterone regulate mammary gland development.</em> 2015. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4596764/">PMC</a>)  </li>
    <li>oakes etâ€¯al. <em>key stages in mammary gland development: the alveolar morphogenesis.</em> 2006. (<a href="https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr1411">BioMed Central</a>)  </li>
    <li>bocchinfuso etâ€¯al. <em>endocrinology</em> 2000. estrogen priming induces pr/prlr in ductal epithelium. (<a href="https://academic.oup.com/endo/article/141/8/2982/2988701">Oxford Academic</a>)  </li>
    <li>de blok etâ€¯al. <em>jcem</em> 2018. most breast growth occurs in the first 6 months of gaht. (<a href="https://pubmed.ncbi.nlm.nih.gov/29165635/">PubMed</a>)  </li>
    <li>dâ€™hoore etâ€¯al. <em>journal of internal medicine</em> 2022 (review). modest volumes after 1 year; many &lt; aaa. (<a href="https://onlinelibrary.wiley.com/doi/10.1111/joim.13441">Wiley Online Library</a>)  </li>
    <li>nolan etâ€¯al. <em>endocrine connections</em> 2022. 100â€¯mg omp for 3 months: no change in sleep/distress/tanner vs controls. (<a href="https://ec.bioscientifica.com/view/journals/ec/11/5/EC-22-0170.xml">Bioscientifica</a>)  </li>
    <li>chang etâ€¯al. <em>transgender health</em> 2025 (in press/online first). survey: many users perceive benefit from progestogens. (<a href="https://www.sciencedirect.com/science/article/pii/S1530891X25009437">ScienceDirect</a>)  </li>
    <li>dijkman etâ€¯al. <em>bmc pharmacology &amp; toxicology</em> 2023. rct protocol: estradiolâ€¯Â±â€¯omp; primary outcome 3â€‘d breast volume. (<a href="https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-023-00724-4">BioMed Central</a>)  </li>
    <li>transdermal estradiol and vte risk: caseâ€‘control/metaâ€‘analytic evidence in cis cohorts; program data in trans cohorts. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10081942/">PMC</a>)</li>
    </ul>
    <hr>
    </article></div><footer class="mt-16 pt-8 border-t"><div class="flex flex-col sm:flex-row justify-between items-center gap-4"><p class="text-sm text-muted-foreground">published 17/08/2025</p><a class="text-sm text-foreground hover:opacity-70 underline" href="/">view all papers</a></div></footer>
</main>
<body class="min-h-screen font-custom antialiased" id="readabilityBody"><p hidden=""></p></body>